Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups (Q84289320)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

childhood acute myeloid leukemia

3 February 2020

main subject

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Christian Thiede

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

F Damm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

F Thol

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

I Hollink

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Zimmermann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

K Reinhardt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M M van den Heuvel-Eibrink

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

C M Zwaan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

V de Haas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

U Creutzig

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J Krauter

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Heuser

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Ganser

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

D Reinhardt

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

7 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

1704-1710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21647152%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.142

3 February 2020

exact match

0 references

cites work

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Pediatric acute myeloid leukemia: international progress and future directions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

FLT3 mutations in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

CEBPalpha mutations in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Recurring mutations found by sequencing an acute myeloid leukemia genome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Metabolism unhinged: IDH mutations in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Low prevalence of IDH1 gene mutation in childhood AML in Italy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

affy--analysis of Affymetrix GeneChip data at the probe level

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

A method and server for predicting damaging missense mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021

Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.142

7 January 2021